fire-4.5: folfoxiri plus either bevacizumab or cetuximab as 1l treatment of braf v600e-mutant mcrc
Published 1 year ago • 220 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
4:25
fire-4.5: folfoxiri plus either bevacizumab or cetuximab in mcrc
-
2:45
1l folfoxiri plus cetuximab or bevacizumab for ras wild-type mcrc
-
1:04
deeper: folfoxiri cetuximab or bevacizumab for 1l mcrc
-
2:11
fire-4: evaluation of 1l efficacy of folfiri/cetuximab in patients with ras-wt mcrc
-
1:45
breakwater: encorafenib plus cetuximab in patients with braf v600e-mutant mcrc
-
3:01
deeper: m-folfoxiri and cetuximab versus bevacizumab in mcrc
-
4:51
colorectal cancer debate: first line braf v600e - folfoxiri/bev
-
3:07
fire-4: influence of baseline liquid biopsy results in 1l efficacy of folfiri/cetux in ras-wt mcrc
-
3:58
dr. cathy eng on bevacizumab plus folfoxiri for patients with mcrc
-
3:15
predictive biomarkers for ras-wt mcrc treated with cetuximab and m-folfoxiri
-
2:40
folfoxiri plus panitumumab vs mfolfox6/pan for unresectable ras and braf wild-type mcc
-
3:41
liquid biopsy results in treatment efficacy of folfiri/cetuximab in patients with tissue ras-wt mcrc
-
4:16
fire-3 study: cetuximab versus bevacizumab in metastatic colorectal cancer
-
8:16
beacon crc: first-line bevacizumab in colorectal cancer treatment
-
3:59
asco 2013: cetuximab superior to bevacizumab for advanced colorectal cancer
-
1:17
treatment approaches for braf v600e mutant metastatic colorectal cancer
-
5:04
beacon: encorafenib plus cetuximab with or without binimetinib for braf v600e–mutant metastatic ...
-
15:09
folfoxiri bevacizumab atezolizumab versus folfoxiri bevacizumab as first-line treatment of...
-
8:16
encorafenib & binimetinib cetuximab for untreated braf v600e-mutant metastatic colorectal cancer